<p>按照大多数指标，股市目前被定价为溢价。但这并不意味着仍然找不到便宜货。</p>
<p>三位 Motley Fool 的撰稿人认为他们已经找到了可以立即购买的超便宜的医疗保健股票。以下是他们选择 <strong>CRISPR Therapeutics</strong>(CRSP -2.65%)、<strong>吉利德科学</strong>(GILD 0.05%) 和 <strong>辉瑞</strong>(PFE -0.81%) 的原因。</p>
<h2>你仍然可以抢占先机</h2>
<p><strong>Prosper Junior Bakiny (CRISPR Therapeutics):</strong> 对于那些几乎没有收入的相对较小的生物技术公司进行估值并不是一门精确的科学。尽管如此，作为一家基因编辑专家，CRISPR Therapeutics 在当前水平看起来很便宜。尽管最近与 <strong>Vertex Pharmaceuticals</strong> 合作开发了治疗两种血液相关疾病的 Casgevy 并获得批准，但 CRISPR Therapeutics 的市值仅为 42 亿美元。</p>
<p>CRISPR Therapeutics 和 Vertex Pharmaceuticals 在 Casgevy 方面面临着巨大的机会。这种药物在美国的价格为 220 万美元。他们估计在美国和欧洲有 3.5 万患者，另外在中东一些国家也获得了批准，有 2.3 万患者。CRISPR Therapeutics 应该能够从 Casgevy 获得超过 10 亿美元的销售额。</p>
<p>该公司还表明其基因编辑平台可以在解锁少有治疗方法的疾病方面产生实质性结果。机会无限：许多疾病没有获得批准的治疗方法。许多其他疾病迫切需要更好的护理标准。CRISPR Therapeutics 更有前途的项目之一是其在 1 型糖尿病方面的工作，公司正试图开发功能性治愈方法。</p>
<p>在我看来，CRISPR Therapeutics 是一个正在崛起的生物技术巨头。Casgevy 将带来资金，帮助推动其基因编辑平台向前发展。在未来五年内，预计该公司将取得更重要的临床和监管进展。尽管自 2016 年首次公开募股（IPO）以来，CRISPR Therapeutics 已经取得了可观的回报，但对于愿意耐心等待的投资者来说，这家生物技术公司仍然有相当大的增长空间。</p>
<h2>吉利德科学可能成为被低估的增长股</h2>
<p><strong>David Jagielski (吉利德科学):</strong> 现在你不想忽视的一家顶级制药股票是哪家？吉利德科学。尽管过去几年其个位数（有时为负数）的增长率看起来并不令人印象深刻，但该公司确实拥有一些有望成为未来增长动力的有利因素。此外，它支付了一笔出色的股息，股息率为 3.7%，几乎是 <strong>标普 500 指数</strong>1.3% 的三倍。</p>
<p>吉利德科学最近宣布，其每年两次的 HIV 治疗药 lenacapavir 在预防 HIV 方面效果显著。在第 3 阶段试验中，它将感染率降低了 96%。分析师估计，这种药物，已经获得批准用于治疗多药耐药性 HIV 的患者，可能在销售高峰期创造 40 亿美元的销售额。去年，吉利德的销售额超过 270 亿美元，这可能成为该公司一个可观的创收产品。</p>
<p>Lenacapavir 可能为公司的 HIV 业务带来奇迹，这一直是吉利德近来增长最慢的业务。在 2024 年上半年，HIV 销售额同比仅增长 3%，达到 91 亿美元。尽管这仍然是公司最大的业务部门，但在该时期，肝病（13%）和肿瘤学（17%）的增长率都远高于此，也代表了未来业务的激动人心的增长机会。</p>
<p>尽管吉利德的股价今年有所上涨，但这家生物技术股票以预期未来利润的 12 倍估值（基于分析师预期）交易。对于长期投资者来说，这可能是一家值得购买并持有的优秀股票。</p>
<h2>超乎寻常</h2>
<p><strong>Keith Speights (辉瑞):</strong> 近年来，辉瑞一直是一家大输家，尽管在 2024 年勉强取得了微薄收益。然而，我相信这家大型药品制造商的内情远不止表面看到的那样。</p>
<p>你可以将辉瑞的许多困境归咎于其 COVID-19 产品销量的下降。我不预计该公司会再次看到 2021 年和 2022 年的蓬勃发展。但我也认为 2024 年可能是辉瑞 COVID-19 疫苗销售的低谷年。</p>
<p>该公司面临的另一个重大挑战是其多款畅销产品即将到期专利。不幸的是，辉瑞的产品列表中包括 Eliquis、Ibrance、Vyndaqel、Xeljanz 和 Xtandi 等畅销药品。</p>
<p>然而，辉瑞并没有被这一专利悬崖所蒙蔽。它已经投资于开发新产品，其中呼吸道合胞病毒（RSV）疫苗 Abrysvo 尤为突出。该公司还利用疫情最严重时期从其 COVID-19 疫苗中获得的巨额现金用于资助关键收购，包括其 2023 年收购 Seagen。因此，尽管多款产品失去专利独家权，辉瑞仍有望在未来几年实现稳健增长。</p>
<p>与此同时，这家制药公司的股价折让。辉瑞的股票仅以未来收益的 10.6 倍交易。这比标普 500 医疗保健行业的未来收益倍数 19.6 要低得多。</p>
<p>如果你正在寻找购买这只超便宜股票的另一个理由，请查看其股息。辉瑞提供 5.65% 的未来股息收益率。更好的是，该公司的管理团队仍致力于随着时间推移增加其股息支付。</p>

吉利德科学

CRISPR治疗

<p>三位 Motley Fool 的撰稿人推荐三只被低估的医疗保健股票：CRISPR Therapeutics、吉利德科学和辉瑞。CRISPR Therapeutics 被视为一家有潜力的生物科技公司，其新治疗药物 Casgevy 有望带来可观的销售额。吉利德科学尽管增长缓慢，但提供丰厚的股息，并从其 HIV 治疗药物 lenacapavir 中获得潜在收益。辉瑞面临来自 COVID-19 产品销售下降和专利到期的挑战，正在投资于新产品和收购，为未来增长做准备。这三只股票被认为是对于有耐心的投资者的不错选择</p>

<p>By most metrics, the stock market is priced at a premium these days. But that doesn't mean bargains can't still be found.</p>
<div class="lb-trans"><p>按照大多数指标，股市目前被定价为溢价。但这并不意味着仍然找不到便宜货。</p>
</div><p>Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked <strong>CRISPR Therapeutics</strong>(CRSP -2.65%), <strong>Gilead Sciences</strong>(GILD 0.05%), and <strong>Pfizer</strong>(PFE -0.81%).</p>
<div class="lb-trans"><p>三位 Motley Fool 的撰稿人认为他们已经找到了可以立即购买的超便宜的医疗保健股票。以下是他们选择 <strong>CRISPR Therapeutics</strong>(CRSP -2.65%)、<strong>吉利德科学</strong>(GILD 0.05%) 和 <strong>辉瑞</strong>(PFE -0.81%) 的原因。</p>
</div><h2>You can still get in on the ground floor</h2>
<div class="lb-trans"><h2>你仍然可以抢占先机</h2>
</div><p><strong>Prosper Junior Bakiny (CRISPR Therapeutics):</strong> Valuing relatively small biotech companies that generate little-to-no revenue is not an exact science. Even so, CRISPR Therapeutics, a gene-editing specialist, looks cheap at its current levels. CRISPR Therapeutics' market cap is $4.2 billion despite the recent approval of Casgevy, a treatment for two blood-related diseases it developed in collaboration with <strong>Vertex Pharmaceuticals</strong>.</p>
<div class="lb-trans"><p><strong>Prosper Junior Bakiny (CRISPR Therapeutics):</strong> 对于那些几乎没有收入的相对较小的生物技术公司进行估值并不是一门精确的科学。尽管如此，作为一家基因编辑专家，CRISPR Therapeutics 在当前水平看起来很便宜。尽管最近与 <strong>Vertex Pharmaceuticals</strong> 合作开发了治疗两种血液相关疾病的 Casgevy 并获得批准，但 CRISPR Therapeutics 的市值仅为 42 亿美元。</p>
</div><p>CRISPR Therapeutics and Vertex Pharmaceuticals are looking at a massive opportunity with Casgevy. The medicine costs $2.2 million in the U.S. They estimate a market of 35,000 patients in the U.S. and Europe, with an additional 23,000 in some countries in the Middle East where Casgevy is also approved. CRISPR Therapeutics should eventually generate well over $1 billion in sales from Casgevy.</p>
<div class="lb-trans"><p>CRISPR Therapeutics 和 Vertex Pharmaceuticals 在 Casgevy 方面面临着巨大的机会。这种药物在美国的价格为 220 万美元。他们估计在美国和欧洲有 3.5 万患者，另外在中东一些国家也获得了批准，有 2.3 万患者。CRISPR Therapeutics 应该能够从 Casgevy 获得超过 10 亿美元的销售额。</p>
</div><p>The company has also shown that its gene-editing platform can produce tangible results in unlocking treatments where few are available. There is a world of opportunities: Plenty of conditions have no approved treatments. Many others have a dire need for better standards of care. One of CRISPR Therapeutics' more promising projects is its work in type 1 diabetes for which the company is attempting to develop a functional cure.</p>
<div class="lb-trans"><p>该公司还表明其基因编辑平台可以在解锁少有治疗方法的疾病方面产生实质性结果。机会无限：许多疾病没有获得批准的治疗方法。许多其他疾病迫切需要更好的护理标准。CRISPR Therapeutics 更有前途的项目之一是其在 1 型糖尿病方面的工作，公司正试图开发功能性治愈方法。</p>
</div><p>In my view, CRISPR Therapeutics is a biotech giant in the making. Casgevy will bring in the funds that will help it push its gene-editing platform forward. In the next five years, expect more important clinical and regulatory progress from the company. Though CRISPR Therapeutics has delivered strong returns since its 2016 initial public offering (IPO), there remains substantial upside for the biotech, at least for investors willing to be patient.</p>
<div class="lb-trans"><p>在我看来，CRISPR Therapeutics 是一个正在崛起的生物技术巨头。Casgevy 将带来资金，帮助推动其基因编辑平台向前发展。在未来五年内，预计该公司将取得更重要的临床和监管进展。尽管自 2016 年首次公开募股（IPO）以来，CRISPR Therapeutics 已经取得了可观的回报，但对于愿意耐心等待的投资者来说，这家生物技术公司仍然有相当大的增长空间。</p>
</div><h2>Gilead Sciences could make for an underrated growth stock</h2>
<div class="lb-trans"><h2>吉利德科学可能成为被低估的增长股</h2>
</div><p><strong>David Jagielski</strong> <strong>(Gilead Sciences):</strong> What's a top pharmaceutical stock you won't want to overlook right now? Gilead Sciences. While its single-digit (and sometimes negative) growth rate may look unimpressive over the past few years, the company does possess some promising catalysts which can lead to stronger numbers in the future. Plus, it pays a great dividend which yields 3.7% -- nearly three times better than the <strong>S&amp;P 500</strong> average of 1.3%.</p>
<div class="lb-trans"><p><strong>David Jagielski (吉利德科学):</strong> 现在你不想忽视的一家顶级制药股票是哪家？吉利德科学。尽管过去几年其个位数（有时为负数）的增长率看起来并不令人印象深刻，但该公司确实拥有一些有望成为未来增长动力的有利因素。此外，它支付了一笔出色的股息，股息率为 3.7%，几乎是 <strong>标普 500 指数</strong>1.3% 的三倍。</p>
</div><p>Gilead Sciences recently announced that lenacapavir, its twice-yearly HIV treatment, was highly effective in preventing HIV. It dramatically reduced infections by 96% in a phase 3 trial. Analysts estimate that the drug, which is already approved to treat people who have multidrug-resistant HIV, could generate $4 billion in sales at its peak. That could be a considerable revenue-generating product for the business as last year Gilead's sales topped $27 billion.</p>
<div class="lb-trans"><p>吉利德科学最近宣布，其每年两次的 HIV 治疗药 lenacapavir 在预防 HIV 方面效果显著。在第 3 阶段试验中，它将感染率降低了 96%。分析师估计，这种药物，已经获得批准用于治疗多药耐药性 HIV 的患者，可能在销售高峰期创造 40 亿美元的销售额。去年，吉利德的销售额超过 270 亿美元，这可能成为该公司一个可观的创收产品。</p>
</div><p>Lenacapavir could do wonders for the company's HIV business, which has been Gilead's slowest growing of late. Through the first six months of 2024, HIV sales rose by just 3% year over year to $9.1 billion. While that's still the company's largest segment, growth rates in liver disease (13%) and oncology (17%) were both far higher during that time frame and also represent exciting growth opportunities for the business in the future.</p>
<div class="lb-trans"><p>Lenacapavir 可能为公司的 HIV 业务带来奇迹，这一直是吉利德近来增长最慢的业务。在 2024 年上半年，HIV 销售额同比仅增长 3%，达到 91 亿美元。尽管这仍然是公司最大的业务部门，但在该时期，肝病（13%）和肿瘤学（17%）的增长率都远高于此，也代表了未来业务的激动人心的增长机会。</p>
</div><p>Although Gilead's shares are up a little this year, the biotech stock trades at a lowly 12 times its estimated future profits (based on analyst expectations). For long-term investors, this could be an excellent stock to buy and hold.</p>
<div class="lb-trans"><p>尽管吉利德的股价今年有所上涨，但这家生物技术股票以预期未来利润的 12 倍估值（基于分析师预期）交易。对于长期投资者来说，这可能是一家值得购买并持有的优秀股票。</p>
</div><h2>More than meets the eye</h2>
<div class="lb-trans"><h2>超乎寻常</h2>
</div><p><strong>Keith Speights (Pfizer):</strong> Pfizer has been a big loser in recent years, although it has eked out a meager gain in 2024. However, I believe there's more than meets the eye with this big drugmaker.</p>
<div class="lb-trans"><p><strong>Keith Speights (辉瑞):</strong> 近年来，辉瑞一直是一家大输家，尽管在 2024 年勉强取得了微薄收益。然而，我相信这家大型药品制造商的内情远不止表面看到的那样。</p>
</div><p>You can blame much of Pfizer's woes on the declining sales of its COVID-19 products. I don't anticipate the company will ever again see the booming numbers of 2021 and 2022. But I also think 2024 could be a trough year for Pfizer's COVID-19 vaccine sales.</p>
<div class="lb-trans"><p>你可以将辉瑞的许多困境归咎于其 COVID-19 产品销量的下降。我不预计该公司会再次看到 2021 年和 2022 年的蓬勃发展。但我也认为 2024 年可能是辉瑞 COVID-19 疫苗销售的低谷年。</p>
</div><p>The other big challenge for the company is the impending patent expirations for several of its top products. Unfortunately for Pfizer, the list includes blockbuster drugs Eliquis, Ibrance, Vyndaqel, Xeljanz, and Xtandi.</p>
<div class="lb-trans"><p>该公司面临的另一个重大挑战是其多款畅销产品即将到期专利。不幸的是，辉瑞的产品列表中包括 Eliquis、Ibrance、Vyndaqel、Xeljanz 和 Xtandi 等畅销药品。</p>
</div><p>Pfizer isn't being blindsided by this patent cliff, though. It has invested in developing new products, with respiratory syncytial virus (RSV) vaccine Abrysvo especially standing out. The company has also used the tremendous cash generated from its COVID-19 vaccine during the worst of the pandemic to fund key acquisitions, including its 2023 purchase of Seagen. As a result, Pfizer should be able to deliver solid growth in the coming years despite losing patent exclusivity for multiple products.</p>
<div class="lb-trans"><p>然而，辉瑞并没有被这一专利悬崖所蒙蔽。它已经投资于开发新产品，其中呼吸道合胞病毒（RSV）疫苗 Abrysvo 尤为突出。该公司还利用疫情最严重时期从其 COVID-19 疫苗中获得的巨额现金用于资助关键收购，包括其 2023 年收购 Seagen。因此，尽管多款产品失去专利独家权，辉瑞仍有望在未来几年实现稳健增长。</p>
</div><p>Meanwhile, the pharma stock is priced at a discount. Pfizer's shares trade at only 10.6 times forward earnings. That's much lower than the S&amp;P 500 healthcare sector's forward-earnings multiple of 19.6.</p>
<div class="lb-trans"><p>与此同时，这家制药公司的股价折让。辉瑞的股票仅以未来收益的 10.6 倍交易。这比标普 500 医疗保健行业的未来收益倍数 19.6 要低得多。</p>
</div><p>If you're looking for another reason to buy this dirt-cheap stock, check out its dividend. Pfizer offers a forward-dividend yield of 5.65%. Even better, the company's management remains committed to growing its dividend payout over time.</p>
<div class="lb-trans"><p>如果你正在寻找购买这只超便宜股票的另一个理由，请查看其股息。辉瑞提供 5.65% 的未来股息收益率。更好的是，该公司的管理团队仍致力于随着时间推移增加其股息支付。</p>
</div>

当前值得买入的 3 只超便宜股票